4DX · ASX

4DMedical Ltd (ASX:4DX)

AU$0.29

 -0.025 (-7.937%)
ASX:Live
28/03/2025 04:10:47 PM
Near Support Near 52 Week Low HALO Ords HALO Consensus Value GROWTH AUS +2
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

4DX Overview

4DX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Strong

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About 4DX

Telephone

Address

Description

4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. It develops pipeline products that may assist physicians to more effectively diagnose and manage patients with lung disease, which includes XV ventilation analysis, ventilation perfusion, contrast free pulmonary angiography, small animal ventilator, and preclinical scanner. The company was founded by Andreas Fouras in December 2012 and is headquartered in Carlton, Australia.

4DX Price Chart

Key Stats

Market Cap

AU$144.13M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.31 - 0.71

Trade Value (12mth)

AU$92,331.00

1 week

-16%

1 month

-18.18%

YTD

-34.37%

1 year

-51.54%

All time high

2.98

Key Fundamentals

EPS 3 yr Growth

18.60%

EBITDA Margin

%

Operating Cashflow

-$31m

Free Cash Flow Return

-40.90%

ROIC

-47.70%

Interest Coverage

-167.30

Quick Ratio

1.70

Other Data

Shares on Issue (Fully Dilluted)

413m

HALO Sector

Next Company Report Date

28-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.09

4DX Announcements

Latest Announcements

Date Announcements

26 March 25

Cost reduction program delivers $6.5m in annualised savings

×

Cost reduction program delivers $6.5m in annualised savings

25 March 25

4DMedical completes oversubscribed $8.4m SPP

×

4DMedical completes oversubscribed $8.4m SPP

25 March 25

Application for quotation of securities - 4DX

×

Application for quotation of securities - 4DX

25 March 25

Prospectus

×

Prospectus

25 March 25

Target Market Determination

×

Target Market Determination

11 March 25

3-year contract extension secured with the Cleveland Clinic

×

3-year contract extension secured with the Cleveland Clinic

03 March 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

03 March 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

03 March 25

Notification of cessation of securities - 4DX

×

Notification of cessation of securities - 4DX

28 February 25

Appendix 4D and Half-Year Report

×

Appendix 4D and Half-Year Report

28 February 25

1H FY2025 Half-year results

×

1H FY2025 Half-year results

28 February 25

1H FY2025 Investor Presentation

×

1H FY2025 Investor Presentation

28 February 25

Cleansing Notice - Placement

×

Cleansing Notice - Placement

28 February 25

Change in substantial holding

×

Change in substantial holding

28 February 25

Change in substantial holding

×

Change in substantial holding

28 February 25

Change in substantial holding

×

Change in substantial holding

27 February 25

Webinar details - 1H FY2025 Half Year Results

×

Webinar details - 1H FY2025 Half Year Results

27 February 25

Application for quotation of securities - 4DX

×

Application for quotation of securities - 4DX

27 February 25

Update - Proposed issue of securities - 4DX

×

Update - Proposed issue of securities - 4DX

25 February 25

4DMedical gains regulatory approval for CT LVAS in Canada

×

4DMedical gains regulatory approval for CT LVAS in Canada

25 February 25

Cleansing Notice - SPP

×

Cleansing Notice - SPP

25 February 25

Share Purchase Plan Offer Booklet

×

Share Purchase Plan Offer Booklet

21 February 25

4DMedical completes Placement & launches underwritten SPP

×

4DMedical completes Placement & launches underwritten SPP

21 February 25

INVESTOR PRESENTATION - CAPITAL RAISE

×

INVESTOR PRESENTATION - CAPITAL RAISE

21 February 25

Webinar Details - Capital Raise

×

Webinar Details - Capital Raise

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.09%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

4DX Shortsell

Frequently Asked Questions

The current share price of 4DMedical Ltd (4DX:ASX) is AU$0.29.
The 52-week high share price for 4DMedical Ltd (4DX:ASX) is AU$0.71.
The 52-week low share price for 4DMedical Ltd (4DX:ASX)? is AU$0.31.
4DMedical Ltd (4DX:ASX) does not pay a dividend.
4DMedical Ltd (4DX:ASX) does not pay a dividend.
4DMedical Ltd (4DX:ASX) has a franking level of 0.0%.
4DMedical Ltd (4DX:ASX) is classified in the Technology.
The current P/E ratio for 4DMedical Ltd (4DX:ASX) is .